Bivalirudin
Also known as: Angiomax, Hirulog
Bivalirudin is a synthetic anticoagulant peptide that directly inhibits thrombin, preventing blood clot formation during cardiovascular procedures. This reversible direct thrombin inhibitor offers predictable anticoagulation with a short half-life and minimal drug interactions.
Bivalirudin is a 2180.29 g/mol research peptide. Bivalirudin is a synthetic anticoagulant peptide that directly inhibits thrombin, preventing blood clot formation during cardiovascular procedures. This reversible direct thrombin inhibitor offers predictable anticoagulation with a short half-life and minimal drug interactions.
Also called: Angiomax, Hirulog
2180.29 g/mol
Molecular Weight
Daltons
4
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
0.75-0.75
Typical Dose
mg/kg
Overview
Bivalirudin functions as a 20-amino acid synthetic peptide derived from hirudin, the natural anticoagulant found in medicinal leeches. Unlike heparin-based anticoagulants, bivalirudin binds directly to both the active site and exosite I of thrombin, creating reversible inhibition that allows for precise control of coagulation. The peptide undergoes proteolytic cleavage by thrombin itself, which releases the active site and allows coagulation function to gradually return. This unique mechanism provides predictable pharmacokinetics without requiring antithrombin III as a cofactor. Research applications focus on cardiovascular procedures, particularly percutaneous coronary interventions where controlled anticoagulation is essential. The peptide's rapid onset and offset make it valuable for procedures requiring immediate hemostatic control.
Key Takeaways: Bivalirudin
- Strongest evidence supports Bivalirudin for direct thrombin inhibition and reduced bleeding risk
- Research doses typically range from 0.75 to 0.75 mg/kg via intravenous bolus
- 4 benefits with strong evidence, 3 moderate, 0 preliminary
- Half-life: 25 minutes (normal renal function)
- 4 cited research studies in this guide
Mechanism of Action
Bivalirudin binds specifically to thrombin through a two-step mechanism. The peptide's C-terminal region binds to thrombin's fibrinogen recognition exosite (exosite I) while the N-terminal region occupies the active site cleft. This dual binding creates competitive inhibition of thrombin's ability to convert fibrinogen to fibrin and activate coagulation factors V, VIII, and XIII. Thrombin cleaves the Arg3-Pro4 bond in bivalirudin's N-terminal region, releasing the active site portion and allowing gradual return of thrombin activity. The remaining C-terminal fragment continues to bind exosite I but with significantly reduced inhibitory effect.
Research Benefits
Bivalirudin at a Glance
Bivalirudin binds specifically to thrombin through a two-step mechanism.
Direct Thrombin Inhibition
Strong EvidenceProvides immediate and reversible anticoagulation by directly binding to thrombin's active site and exosite I, unlike indirect inhibitors that require cofactors. This mechanism allows for predictable dose-response relationships in cardiovascular procedures.
Reduced Bleeding Risk
Strong EvidenceDemonstrates lower rates of major bleeding compared to heparin plus glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions. The short half-life allows rapid reversal of anticoagulant effects when bleeding occurs.
Heparin-Induced Thrombocytopenia Alternative
Strong EvidenceServes as primary anticoagulant for patients with heparin-induced thrombocytopenia (HIT) during cardiac procedures, as it does not interact with platelet factor 4 antibodies that cause HIT.
Predictable Pharmacokinetics
Strong EvidenceExhibits linear dose-response relationship with minimal individual variability, eliminating need for routine coagulation monitoring during standard procedures. Clearance occurs primarily through proteolytic degradation rather than hepatic metabolism.
Reduced Ischemic Events
Moderate EvidenceClinical trials show decreased rates of death, myocardial infarction, and urgent revascularization compared to heparin-based regimens in acute coronary syndrome patients undergoing PCI.
Renal Function Preservation
Moderate EvidenceStudies suggest lower incidence of contrast-induced nephropathy compared to heparin-based anticoagulation, particularly relevant in patients with pre-existing renal impairment undergoing catheter procedures.
Minimal Drug Interactions
Moderate EvidenceDoes not require antithrombin III as cofactor and shows minimal interactions with other cardiovascular medications, simplifying anticoagulation management in complex patients.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Percutaneous coronary intervention | 0.75–0.75 mg/kg | intravenous bolus |
| PCI maintenance infusion | 1.75–1.75 mg/kg/hr | intravenous infusion |
| Acute coronary syndrome | 0.1–0.25 mg/kg/hr | intravenous infusion |
| HIT with thrombosis | 0.15–0.2 mg/kg/hr | intravenous infusion |
Frequency
Continuous infusion with initial bolus
Timing
Initiated immediately before procedure
Cycle Length
Duration of procedure plus 4 hours post-PCI
Research Notes
- 1Reduce dose by 20% if creatinine clearance 30-59 mL/min
- 2Reduce dose by 60% if creatinine clearance 10-29 mL/min
- 3Monitor ACT to maintain 300-350 seconds during PCI
- 4No reversal agent available - cessation allows rapid effect dissipation
- 5For research purposes only - not for human therapeutic use
Reconstitution Guide
Standard Reconstitution
Vial Size
250 mg
Bacteriostatic Water
5 mL
Concentration
500 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Bivalirudin vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 5 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C. 24 hours after reconstitution.
Storage Temperature
2-8°C
Shelf Life
24 hours after reconstitution
Important Notes
- •Reconstitute with sterile water for injection
- •Gently swirl to dissolve - do not shake vigorously
- •Further dilute in normal saline or 5% dextrose for infusion
- •Final concentration should not exceed 5 mg/mL
- •Use within 24 hours of preparation
- •Discard if solution becomes discolored or contains particulates
Bivalirudin Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Bivalirudin Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Major bleeding (intracranial, gastrointestinal, retroperitoneal)
- !Minor bleeding at injection sites
- !Back pain (mechanism unclear)
- !Nausea and vomiting
- !Hypotension during administration
- !Headache
- !Injection site pain or reaction
- !Bradycardia
- !Allergic reactions (rare)
- !Thrombocytopenia (uncommon)
Potential Interactions
- ⚡Warfarin and other oral anticoagulants increase bleeding risk
- ⚡Antiplatelet agents (aspirin, clopidogrel) enhance bleeding potential
- ⚡NSAIDs may increase bleeding complications
- ⚡Thrombolytic agents create additive bleeding risk
- ⚡Glycoprotein IIb/IIIa inhibitors significantly increase hemorrhage risk
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina
Randomized trial showing bivalirudin reduced ischemic events compared to heparin in 4312 patients undergoing coronary angioplasty for unstable angina.
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention
ACUITY trial demonstrated bivalirudin alone reduced bleeding while maintaining efficacy compared to heparin plus glycoprotein IIb/IIIa inhibitors in 13,819 patients.
Bivalirudin during primary PCI in acute myocardial infarction
HORIZONS-AMI trial showed bivalirudin reduced bleeding and mortality compared to heparin plus glycoprotein IIb/IIIa inhibitors in primary PCI patients.
Pharmacokinetics and pharmacodynamics of bivalirudin in patients with renal impairment
Study establishing dose adjustment requirements for bivalirudin in patients with varying degrees of renal impairment undergoing cardiovascular procedures.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Bivalirudin is primarily researched as an anticoagulant for cardiovascular procedures, particularly percutaneous coronary interventions. Studies focus on its efficacy compared to heparin-based regimens and its use in patients with heparin-induced thrombocytopenia.
Bivalirudin directly inhibits thrombin without requiring antithrombin III as a cofactor, while heparin works indirectly through antithrombin III. Bivalirudin has more predictable pharmacokinetics and does not cause heparin-induced thrombocytopenia.
Bivalirudin has a half-life of approximately 25 minutes in patients with normal renal function. The half-life extends significantly in patients with renal impairment, requiring dose adjustments.
No specific reversal agent exists for bivalirudin. However, its short half-life means anticoagulant effects dissipate rapidly after discontinuation, typically within 1-2 hours in patients with normal kidney function.
Activated clotting time (ACT) is typically monitored during percutaneous coronary interventions to maintain levels between 300-350 seconds. Unlike heparin, bivalirudin shows predictable dose-response relationships.
The most significant side effect is bleeding, particularly at vascular access sites. Other common effects include back pain, nausea, and hypotension during administration. Major bleeding rates are generally lower than with heparin-based regimens.
Bivalirudin can be used in patients with renal impairment but requires dose reduction. Patients with creatinine clearance 30-59 mL/min need 20% dose reduction, while those with 10-29 mL/min require 60% reduction.
Bivalirudin is eliminated within 4-6 hours in patients with normal renal function due to its 25-minute half-life. Elimination is prolonged in patients with kidney impairment, extending up to several hours.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.